189 related articles for article (PubMed ID: 34023101)
1. Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:: The Era of Oncodermatopathology.
Curry JL; Chon SY; Marques-Piubelli ML; Chu EY
Surg Pathol Clin; 2021 Jun; 14(2):209-224. PubMed ID: 34023101
[TBL] [Abstract][Full Text] [Related]
2. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
3. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
5. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
Thompson LL; Krasnow NA; Chang MS; Yoon J; Li EB; Polyakov NJ; Molina GE; Said JT; Huang K; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
JAMA Dermatol; 2021 May; 157(5):577-582. PubMed ID: 33760001
[TBL] [Abstract][Full Text] [Related]
7. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.
Tetzlaff MT; Tang S; Duke T; Grabell DA; Cabanillas ME; Zuo Z; Yao JC; Nagarajan P; Aung PP; Torres-Cabala CA; Duvic M; Prieto VG; Huen A; Curry JL
J Cutan Pathol; 2019 Nov; 46(11):872-877. PubMed ID: 31254410
[TBL] [Abstract][Full Text] [Related]
8. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
9. The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.
Seervai RNH; Friske SK; Chu EY; Phillips R; Nelson KC; Huen A; Cho WC; Aung PP; Torres-Cabala CA; Prieto VG; Curry JL
J Cutan Pathol; 2023 Jan; 50(1):72-95. PubMed ID: 36069496
[TBL] [Abstract][Full Text] [Related]
10. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen ST; Semenov YR; Alloo A; Bach DQ; Betof Warner A; Bougrine A; Burton L; Cappelli LC; Castells M; Cohen J; Dewan AK; Fadden R; Guggina L; Hegde A; Huang V; Johnson DB; Kaffenberger B; Kroshinsky D; Kwatra S; Kwong B; Lacouture ME; Larocca C; Leventhal J; Markova A; McDunn J; Mooradian MJ; Naidoo J; Choi J; Nambudiri V; Nelson CA; Patel AB; Pimkina J; Rine J; Rubin KM; Sauder M; Shaigany S; Shariff A; Sullivan RJ; Zubiri L; Reynolds KL; LeBoeuf NR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599660
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.
Kaunitz GJ; Loss M; Rizvi H; Ravi S; Cuda JD; Bleich KB; Esandrio J; Sander I; Le DT; Diaz LA; Brahmer JR; Drake CG; Hollmann TJ; Lacouture ME; Hellmann MD; Lipson EJ; Taube JM
Am J Surg Pathol; 2017 Oct; 41(10):1381-1389. PubMed ID: 28817405
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S; Pahalyants V; Kalinich M; Murphy W; Yu KH; Wang F; Chen ST; Reynolds K; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2022 Mar; 86(3):563-572. PubMed ID: 33819538
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T
Marques-Piubelli ML; Seervai RNH; Mudaliar KM; Ma W; Milton DR; Wang J; Muhlbauer A; Parra ER; Solis LM; Nagarajan P; Speiser J; Hudgens C; Cho WC; Aung PP; Patel A; Pacha O; Nelson KC; Tetzlaff MT; Amaria RN; Torres-Cabala CA; Prieto VG; Wistuba II; Curry JL
J Cutan Pathol; 2023 Jul; 50(7):661-673. PubMed ID: 37150813
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
15. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
16. Mucocutaneous adverse events to immune checkpoint inhibitors.
Muhaj F; Karri PV; Moody W; Brown A; Patel AB
Front Allergy; 2023; 4():1147513. PubMed ID: 36938327
[TBL] [Abstract][Full Text] [Related]
17. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
18. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]